#High Throughput Screening Market Share

[blog-site-for-market-research]

Global High Throughput Screening Market Size| Growth | Scope, 2032

Market Overview

The global high throughput screening market is expected to mature at a 7.5% CAGR during the forecast period.

Market Highlights

High throughput screening has achieved mainstream acceptance over the past two decades and has become a traditional drug discovery tool in the pharmaceutical industry. Factors such as technical developments in HTS and rising pharmaceutical R&D spending are driving the global high throughput screening industry. In addition, demand development is projected to be powered by the growing research activities in stem cells & toxicology and emerging markets. In recent years, technological developments such as liquid handling automation, the development of novel technology systems, and computational methods to deal with vast volumes of data have increasingly powered the global demand for high-performance screening instruments. Rising rivalry for pioneering drug development and marketing demand for high-performance screening instruments among pharmaceutical firms is growing at a rapid rate.

Strong capital spending, on the other hand, is expected to hamper demand growth during the projected period. In addition, the high time consumption and high cost of high-throughput screening techniques can impede the growth of the market.

Segmental Analysis

Based on product & service, technology, applications, end user, and region, the global high throughput screening market has been segmented.

The global market has been bifurcated into reagents & assay kits, instruments, consumables & accessories, software and services, based on product & service.

Due to the large number of reagents and assay kits used in HTS techniques and increased government funding for life science research, the reagents & assay kits segment is expected to hold a significant share in the market.

Segmental Analysis

The worldwide market is divided into cell-based assays, 2D cell culture, 3D cell culture, 3D cell culture, perfusion cell culture, laboratory-on-a-chip (LOC), ultra-high-throughput screening, bioinformatics, and label-free technology based on technology.

Based on use, the global market is segmented into target recognition & confirmation, primary and secondary screening, toxicology assessment, and others. Due to rising pharmaceutical R&D and the increasing prevalence of many diseases, the application category is projected to be the fastest-growing.

The global market is categorised into pharmaceutical and biotechnology firms, university and government agencies, contract research organisations, and others, depending on end users.

Regional Overview

North America and Latin America have been segmented into the high-performance scanning industry in the Americas, with the North American market split into the US and Canada.

Due to the rising per capita healthcare spending and the fast penetration of advanced technologies in the region, the demand in the Americas is projected to dominate the global high throughput screening market. It is expected that the will adoption of HTS in the US and Canada will fuel the growth of the sector. In addition, growing spending on research by healthcare institutions is expected to boost demand growth in this field.

In Europe, the market was projected to see a substantial amount of growth. The existence of a well-established healthcare sector and the participation of main corporations can be attributed to this.

Leading to a rise in chronic diseases and rising government measures for health care reforms, the Asia-Pacific market is expected to have a steady growth rate during the forecast period.

The Middle East & Africa market is estimated to account for the lowest share of the global market because of the region's low per capita disposable income.

Competitive Dashboard

The key players operating in the global high throughput screening market research are Aurora Biomed Inc. (Canada), Danaher (US), PerkinElmer (US), Tecan (Switzerland), Hamilton (US), Axxam (Italy), Merck Group (Germany), Corning (US), BioTek (US), Beckman Coulter, Inc. (US), Agilent Technologies Inc. (US), Luminex Corporation (US), and Roche (Switzerland).

About Market Research Future:

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Contact Us:

Market Research Future (Part of Wantstats Research and Media Private Limited)

99 Hudson Street, 5Th Floor

New York, NY 10013

United States of America

+1 628 258 0071 (US)

+44 2035 002 764 (UK)

Email: sales@marketresearchfuture.com

Website: https://www.marketresearchfuture.com

[markettrend24]

High-Throughput Screening Market Growth, Overview with Detailed Analysis 2022-2028

High-Throughput Screening Market Growth, Overview with Detailed Analysis 2022-2028

The High-Throughput Screening Market research report 2022-2030 provides an in-depth analysis of the changing trends, opportunities, and challenges influencing the growth over the next decade. The study includes a detailed summary of each market along with data related to demand, supply and distribution. The report examines High-Throughput Screening market growth strategies adopted by leading…

[health-views-updates]

Global Cell Signaling Market Size, Share, Segmentations and Forecast 2032 by Industry Key Players, Solutions and Deployment Types

The global cell signaling market is expected to experience significant growth over the coming decade, with market size forecast to expand from USD 5.1 billion in 2023 to USD 9.4 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 7.1% from 2024 to 2032, driven by advancements in biotechnology, pharmaceuticals, and the growing demand for targeted therapies in cancer and chronic diseases.

Cell signaling refers to the complex system of communication that governs basic cellular activities and coordinates cell actions. It is a critical process in maintaining homeostasis, as well as in the development of diseases. This intricate communication system is central to understanding a wide range of physiological processes and pathologies, including cancer, immunology, and neurobiology.

Key Market Drivers

Rising Prevalence of Chronic Diseases: One of the primary drivers of growth in the cell signaling market is the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders. These diseases often result from disrupted or abnormal cell signaling pathways. Consequently, there is a growing demand for research into targeted therapies that can precisely modulate these signaling pathways to treat such conditions. The development of drugs that act on specific signaling molecules has become a major area of focus in the pharmaceutical industry, driving market expansion.

Technological Advancements in Molecular Biology: Rapid advancements in molecular biology and biotechnology have led to breakthroughs in understanding cell signaling pathways. Technologies such as CRISPR gene editing, high-throughput screening, and next-generation sequencing are enabling researchers to study signaling networks at unprecedented levels of detail. These innovations have spurred the development of new diagnostic tools and therapeutic approaches aimed at modulating cell signaling in disease states.

Increasing Focus on Personalized Medicine: The shift toward personalized medicine, where treatments are tailored to an individual’s genetic makeup and specific cellular processes, is another major factor propelling the growth of the cell signaling market. By gaining a better understanding of an individual’s cell signaling pathways, healthcare providers can develop more effective and less toxic treatment plans, particularly for complex conditions like cancer. Personalized medicine is revolutionizing healthcare, and cell signaling research is at the heart of these innovations.

Investment in Cancer Research: Cell signaling research plays a critical role in oncology, as cancer is often driven by mutations in signaling pathways that control cell growth, division, and death. The market is benefiting from substantial investments in cancer research, with a focus on discovering and developing novel therapies that target specific signaling molecules or pathways involved in tumor progression. The introduction of targeted therapies, such as tyrosine kinase inhibitors and immunotherapies, has already transformed cancer treatment and continues to drive growth in this sector.

Get Free Sample Report: https://www.snsinsider.com/sample-request/4501 

Challenges and Opportunities

While the cell signaling market shows great potential, there are challenges that may affect growth. The complexity of cell signaling pathways, the high cost of research, and the time required to develop effective therapies can be significant barriers to market entry. Additionally, regulatory hurdles for new therapies targeting cell signaling molecules can slow down the approval process.

However, these challenges present opportunities for further innovation. Continued research into unexplored signaling pathways and the application of cutting-edge technologies like artificial intelligence (AI) in drug discovery are expected to drive new developments. AI and machine learning are already being used to predict signaling pathway interactions and optimize drug candidates, streamlining the drug development process and reducing costs.

Regional Insights

North America is the largest market for cell signaling, owing to the region’s robust biopharmaceutical industry, high investment in healthcare research, and the presence of key players in the field. The U.S. leads in funding for cancer research and targeted therapies, driving significant demand for cell signaling technologies. Europe follows closely, with a strong focus on advancing research in molecular biology and biotechnology.

The Asia-Pacific region is expected to see the fastest growth during the forecast period, supported by increasing government investments in life sciences, expanding pharmaceutical manufacturing, and growing healthcare infrastructure. China, India, and Japan are becoming prominent markets for cell signaling research due to rising healthcare needs and a growing focus on innovative treatments.

Future Outlook

The cell signaling market is poised for sustained growth as demand for precision medicine and advanced therapies continues to rise. With a projected CAGR of 7.1% from 2024 to 2032, the market is set to reach USD 9.4 billion by 2032. As the understanding of cellular communication deepens and new technologies emerge, the market is expected to play a pivotal role in the development of next-generation treatments for a range of diseases, including cancer, autoimmune disorders, and neurological conditions.

In conclusion, the global cell signaling market is on a steady upward trajectory, driven by advancements in biotechnology, growing investment in cancer research, and the increasing focus on personalized medicine. From USD 5.1 billion in 2023, the market is expected to grow to USD 9.4 billion by 2032, reshaping the landscape of drug discovery and disease treatment.

Other Trending Reports

Defibrillator Market

Healthcare Waste Management Market

PET Scanners Market

Antidepressants Market

[tamanna31]

New Trends of Oligonucleotide Synthesis Market with Industry Analysis by 2024 – 2030

Oligonucleotide Synthesis Industry Overview

The global oligonucleotide synthesis market size was estimated at USD 3.68 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 13.21% from 2024 to 2030. 

The decreasing prices of sequencing have led to increasing demand for custom-made nucleotides for applications across genetic testing, research, forensics applications, and drug development. This has further boosted the demand for oligonucleotide synthesis. The COVID-19 pandemic has affected every market globally and there has been a surge in the demand for efficient treatment against COVID-19.

Gather more insights about the market drivers, restrains and growth of the Oligonucleotide Synthesis Market

Oligonucleotide therapeutics hold immense potential for treating chronic conditions such as cardiovascular diseases, cancers, and retinal disorders. Emerging new applications of oligo sequences in multiple fields of biotechnology are expected to increase market growth. Demand for molecular diagnostics in precision care is an important emerging application field for oligonucleotide synthesis.

The introduction of advanced techniques such as CRISPR and high-throughput sequencing for gene expression analysis has simplified the genetic screening and modification of genomes. Such innovations are observed to influence the demand for oligonucleotide synthesis. Manufacturers invest in technology development to enable the production of long Oligonucleotides with higher precision and better yield to cater to the growing need for custom oligos.

The availability of a regulatory environment that supports the progress of genomics is the key factor contributing to the market growth. Changes in the regulatory policies to provide a well-framed environment for advanced biological research and application in human use are expected to influence demand for oligonucleotide synthesis significantly. Stem cells, regenerative medicine, genetic engineering, and synthetic biology are the prominent fields identified with high potential in healthcare. For instance, the International Society for Stem Cell Research (ISSCR) ethics and public policy committee aims to recognize and resolve issues by conducting open discussions. The committee includes experts in ethics, law, and social policy worldwide.

Browse through Grand View Research's Biotechnology Industry Research Reports.

The global optical genome mapping market size was valued at USD 104.1 million in 2023 and is expected to grow at a CAGR of 26.76% from 2024 to 2030. 

The global therapeutic drug monitoring market size was valued USD 1.80 billion in 2023 and is projected to grow at a CAGR of 3.8% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the market include Merck KGaA, Thermo Fisher Scientific, Inc., and Agilent Technologies. These players focus on business strategies such as partnerships/collaborations, product launches, and expansion. Twist Bioscience, Biolegio, and LGC Biosearch Technologies are some of the emerging market participants in the oligonucleotide market. These players primarily focus on expansion and partnerships to strengthen their position in the market.

Key Oligonucleotide Synthesis Companies:

·         Thermo Fisher Scientific, Inc.

·         Merck KGaA

·         Danaher Corporation

·         Dharmacon Inc.

·         Agilent Technologies

·         Bio-synthesis

·         Kaneka Eurogentec S.A

·         LGC Biosearch Technologies

·         Biolegio

·         Twist Bioscience

Recent Developments

In October 2023, IDT inaugurated a new therapeutic manufacturing facility to meet the increasing demand in genomic medicine. The new facility is equipped to support the production of therapeutic oligonucleotides, catering to the expanding needs in the field of genomics and personalized medicine.

In September 2023, Danaher Corporation (Integrated DNA Technologies) introduced a range of xGen NGS products tailored for the Ultima Genomics UG 100TM platform. The suite includes adapters, primers, and universal blockers, catering to various applications such as DNA, RNA, & methylation sequencing workflows. This offering is complemented by IDT's proven hybridization capture chemistry, enhancing versatility for researchers.

In July 2023, Analytix introduced two new instruments designed for organic synthesis, including wavePREP, tailored for oligonucleotide synthesis, and Xelsius, a workstation for multireaction synthesis.

In May 2023, GenScript expanded its life sciences facility in Zhenjiang, Jiangsu, China, to offer a rapid, high-purity oligonucleotide and peptide synthesis service tailored for research & development as well as preclinical applications.

In May 2023, Twist Bioscience and CeGaT GmbH launched the Twist Alliance CeGaT RNA Fusion Panel. This collaborative effort aims to provide a specialized tool for oncology research, facilitating the detection of RNA fusions and enabling transcript variant analysis. RNA fusions, a result of chromosomal arrangements often seen in cancers, can now be efficiently studied using this newly introduced panel.

In February 2023, Fluor Corp. and Agilent Technologies, Inc. collaborated to enhance its oligonucleotide therapeutics manufacturing facility in Frederick, Colorado. Under this collaboration, Fluor is expected to support the project's engineering and procurement. The total value of the project is evaluated at USD 725 million.

Order a free sample PDF of the Oligonucleotide Synthesis Market Intelligence Study, published by Grand View Research.

[businessindustry]

Automatic Wafer Handling System Market Industry, Size, Share and Forecast by 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Automatic Wafer Handling System Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Automatic Wafer Handling System Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Automatic Wafer Handling System Market?

The global automatic wafer handling system market size reached US$ 1.4 billion in 2023. Looking forward, Reports and Insights expects the market to reach US$ 2.9 billion in 2032, exhibiting a growth rate (CAGR) of 8.1% during 2024-2032.

What are Automatic Wafer Handling System?

An automatic wafer handling system is an advanced technology used in semiconductor manufacturing to automate the transport and management of silicon wafers during the production process. This system handles the delicate tasks of loading, unloading, and positioning wafers with precision, minimizing the risk of contamination and damage. Featuring sophisticated robotics, sensors, and control systems, automatic wafer handling systems improve efficiency, accuracy, and throughput in wafer fabrication, leading to higher yields and better overall quality in semiconductor production.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1924

What are the growth prospects and trends in the Automatic Wafer Handling System industry?

The automatic wafer handling system market growth is driven by various factors and trends. The automatic wafer handling system market is experiencing strong growth, driven by rising demand for advanced semiconductor manufacturing technologies and the pursuit of greater production efficiency. As the semiconductor industry expands, there is an increasing emphasis on automating wafer transport and management to enhance accuracy, reduce contamination, and boost throughput. Key growth factors include technological advancements in robotics and automation, the expansion of semiconductor fabrication facilities, and a heightened need for high-quality, reliable semiconductor products. Hence, all these factors contribute to automatic wafer handling system market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Type:

Robotic Handling Systems

Fixed Handling Systems

Portable Handling Systems

By Application:

Semiconductor Manufacturing

Electronics Industry

Automotive Industry

Medical Devices

Others

Market Segmentation By Region:

North America:

United States

Canada

Europe:

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

BENELUX

NORDIC

Rest of Europe

Asia Pacific:

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

Middle East & Africa:

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Applied Materials, Inc.

ASML Holding N.V.

Lam Research Corporation

Tokyo Electron Limited

KLA Corporation

Hitachi High-Technologies Corporation

SCREEN Holdings Co., Ltd.

Axcelis Technologies, Inc.

ASM International N.V.

Advantest Corporation

Teradyne Inc.

Rudolph Technologies, Inc.

Nikon Corporation

View Full Report: https://www.reportsandinsights.com/report/Automatic Wafer Handling System-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[creativeera]

DNA and RNA Sample Preparation Market is Estimated to Witness High Growth Owing to Increasing Adoption

The DNA and RNA sample preparation market involves processes associated with isolation, extraction, purification and quantification of nucleic acids DNA and RNA from various sources like tissues, blood, sperm, cells etc. for downstream applications in genomics, molecular diagnostics, personalized medicine and others. The sample preparation is a critical and initial step before conducting various genomic tests including Next Generation Sequencing, polymerase chain reaction and other assays. Growing awareness and adoption of precision medicine and genetic/molecular testing is driving demand for efficient nucleic acid isolation and downstream analysis.

The Global DNA and RNA Sample Preparation Market is estimated to be valued at US$ 2262.46 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the DNA and RNA sample preparation are Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., DiaSorin S.p.A, F. Hoffmann-La Roche, Miroculus, Inc., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma Aldrich Corp., Tecan Group AG, and Thermo Fisher Scientific, Inc. Growing prominence of personalized medicine is creating opportunities for development of new sample preparation methods and kits which can extract nucleic acids from various types of samples. Rising incidence of chronic and infectious diseases worldwide is increasing diagnostic testing which will propel sample preparation market growth. Global expansion of key market players through acquisitions and partnerships with regional diagnostic labs and research institutes will further augment market revenues. Market Drivers Increasing funding for Genomic and genetic research from government bodies as well as private sector is one of the key factors driving the DNA and RNA Sample Preparation Market Size. Government initiatives aimed at large scale population screening and clinical testing for various genetic disorders, infectious diseases and cancers are also creating demand for high throughput nucleic acid preparation. Growing geriatric population and rising healthcare spending in developing nations also provides growth opportunities for market players in the forecast period.

PEST Analysis Political: Laws and regulations imposed by governments for research using DNA and RNA samples could impact the market. Changes in healthcare policies will also have effects. Economic: Factors like GDP growth, income levels, healthcare spending will drive demand. Rise in research activities and focus on precision medicine boost the market. Social: Growing awareness about personalized medicine and importance of genetic testing are important. Social trends also promote preventive healthcare and wellness. Technological: Advancements in fields like next generation sequencing, lab automation, bioinformatics are key for market growth. Miniaturization and portability of equipment expand applications. Developments in sample collection and storage methods improve efficiency. Geographical regions where the market in terms of value is concentrated include North America and Europe. North America accounts for the largest share in the global market due to presence of well-established healthcare industry and research institutes. Europe also captures notable share due to growing biotech sector and research funding. The Asia Pacific region is projected to be the fastest growing market during the forecast period. This is attributed to factors such as increasing healthcare expenditure, growing awareness, expanding biotech industry and rising government investments in research. Countries like China, India offer growth opportunities as they focus on healthcare infrastructure development.

Get more insights on DNA And RNA Sample Preparation Market

Also read related article on Surgical Robots Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[colinwilson11]

Smart Drug Design Through Fragment-Based Approaches Will Drive Growth In The Global Fragment Based Drug Discovery Market

The fragment based drug discovery approach involves screening libraries of very small molecules called fragments that bind to targets of therapeutic interest with low molecular weight and high binding efficiency. These fragments act as starting points for developing potential drug candidates. Compared to high-throughput screening, fragment-based methods require smaller libraries that can be easily synthesized and screened. Fragment hits have low affinity but high efficiency that improves the probability of growing them into potent and selectiveligands through structure based drug design.

The Global Fragment Based Drug Discovery Market is estimated to be valued at US$ 0.795 Bn in 2024 and is expected to exhibit a CAGR of 15% over the forecast period 2024-2031.

Key players operating in the fragment based drug discovery market include Astex Pharmaceuticals, Beactica AB, Charles River Laboratories International, Inc., Evotec AG, and Alveus Pharmaceuticals Pvt. Ltd.

Key Takeaways

Key players operating in the fragment based drug discovery market are focusing on expanding their fragment libraries and enhancing screening capabilities to identify novel hits. For instance, in 2022, Astex Pharmaceuticals significantly expanded its fragment library collection to over 450,000 fragments to enable robust hit identification.

The growing incidence of chronic diseases coupled with rising drug discovery and development activities is fueling the demand for fragment-based techniques. Fragment based screening allows developing biologically relevant leads with superior physiochemical and pharmacological properties compared to high-throughput screening.

Technological advancements in biophysical methods such as NMR, crystallography, mass spectrometry and computational modeling tools have widened the application scope of fragment based approaches in hit identification and optimization stages of drug R&D. In 2023, Evotec AG introduced the PanOmics platform to integrate omics data for enhancing fragment hits using systems chemical biology approaches.

Market Trends

De-risking drug candidates: Fragment based screening enables identifying low risk hits bound to attractive regions of target proteins with high efficiency. By optimizing these fragments, drug candidates with lower biological and chemical liability can be developed.

Integrating biophysical methods: Combining multiple biophysical techniques such as X-ray crystallography, NMR spectroscopy, SPR, and SBM provides comprehensive structural and binding information for fragment evolutions and optimization.

Leveraging artificial intelligence: Machine learning and deep learning based computational tools are being increasingly used to process, analyze and interpret large experimental datasets generated through fragment screening campaigns to facilitate hit discovery and design.

Market Opportunities

Growing collaboration between pharmaceutical companies and academic research institutes is expected to boost knowledge sharing and resource optimization for fragment libraries creation and screening. Moreover, increasing R&D investments and funding support from governments and private organizations will facilitate clinical research on fragment-derived drug candidates.

Impact Of COVID-19 On Global Fragment Based Drug Discovery Market:

The COVID-19 pandemic has significantly impacted the Global Fragment Based Drug Discovery Market. During the initial lockdown phase, drug discovery activities were disrupted as research labs and facilities were shut down to curb the virus spread. This led to delays in lab experiments, screening programs and drug development timelines. Researchers faced difficulties in accessing facilities for fragment screening, biophysical analyses and hit validation studies. Supply chain disruptions also created shortages of laboratory consumables and reagents required for fragment based screening assays.

However, as restrictions eased in late 2020, companies resumed operations with new safety protocols. Many shifted their focus towards developing treatments and vaccines for COVID-19. Fragments screening emerged as a promising approach for rapidly identifying potent antiviral hits against the SARS-CoV-2 virus. Several academic and pharmaceutical institutions employed their expertise and infrastructure in fragment based drug design to speed up the search for COVID-19 therapies. Government and private funding also increased for coronavirus drug development projects utilizing fragment screening techniques.

Going forward, companies are expected to leverage learnings from the pandemic. More efficient hybrid models blending onsite and remote working may be adopted. Fragment screening capabilities will be expanded to enable rapid response against future health emergencies. Enhanced collaborations between industry and academia can help expedite drug discovery programs. Overall, with resurgence plans and improved resilience, the long-term impact of COVID-19 on the fragmented based drug discovery market is expected to be positive.

Geographical Regions Of Concentrated Market Value:

The global fragmented based drug discovery market in terms of value is highly concentrated in North American and European countries. The United States holds the largest market share currently due to strong presence of leading pharmaceutical and biotechnology companies. Many top players have their core research and development centres located in the US and are involved in internal and collaborative fragment screening programs. Europe is also a major revenue generator owing to substantial investments in drug discovery research by both private sector and government research councils in countries like Germany, United Kingdom and France.

Fastest Growing Region:

The Asia Pacific region is anticipated to experience the highest growth in the global fragmented based drug discovery market over the forecast period. Factors such as increasing government focus on enhancing domestic innovation, rising biopharmaceutical industry investments, and growing skilled workforce availability are fueling market expansion in Asia Pacific. Countries like China, India and South Korea are emerging hubs for low-cost high quality contract research and manufacturing. This is attracting several multinational companies to establish fragment screening centers and collaborations in Asia to tap growth opportunities. Additionally, improving Intellectual Property (IP) frameworks and favorable business policies will further support market penetration of fragmented based drug discovery technologies across Asia Pacific.

Get more insights on this topic:https://www.trendingwebwire.com/global-fragment-based-drug-discovery-market-is-estimated-to-witness-high-growth-owing-to-technological-advancement-in-fragment-based-screening-techniques/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Global Fragment Based Drug Discovery Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Global Fragment Based Drug Discovery Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Global Fragment Based Drug Discovery Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Global Fragment Based Drug Discovery Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Global Fragment Based Drug Discovery Market vendors

FAQ’s

Q.1 What are the main factors influencing the Global Fragment Based Drug Discovery Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Global Fragment Based Drug Discovery Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Global Fragment Based Drug Discovery Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[hyhealth]

Why Should We Choose Digital X-ray Systems?

How Many Types of X-ray Machines Are There?

Over the years, X-ray technology has evolved significantly, introducing different types of machines tailored to various medical needs. The journey began with analog X-ray machines, which relied on physical film to capture images. Next came Computed Radiography (CR) systems, which used imaging plates instead of film. Today, Digital Radiography (DR) systems lead the market, directly capturing and displaying images digitally. Each type brings its own advantages, but DR systems stand out for their efficiency and superior image quality.

What is a Digital X-ray System?

Digital X-ray systems represent the forefront of radio-graphic technology. Unlike analog and CR systems, DR systems instantly convert X-ray signals into digital images, displayed directly on a computer. Although digital X-rays do use radiation, the amount is considerably lower compared to traditional systems. The advanced detectors in DR systems are designed to capture high-quality images while minimizing radiation exposure, ensuring patient safety without compromising diagnostic accuracy.

Why Are Digital X-rays Better Than Film X-rays?

The superiority of digital X-rays over film X-rays is evident in several key areas. Firstly, digital X-rays provide immediate image results, drastically reducing the time needed for diagnosis, which can be critical in emergencies. Additionally, digital images can be easily shared across healthcare networks, fostering better collaboration among medical professionals. The elimination of chemical processing also makes digital X-rays more environmentally friendly. Over time, the cost savings from not needing film, chemicals, and storage space further highlight the advantages of digital X-rays.

Digital vs. Analog X-ray: The Ultimate Comparison

When comparing digital X-rays to analog X-rays, the differences are striking. Analog X-rays, though effective, involve a cumbersome and time-consuming process of film development. They also expose patients to higher levels of radiation and incur ongoing costs for film and chemicals. In contrast, digital X-rays offer a streamlined process with immediate results, lower radiation doses, and significant cost savings over time. For healthcare providers and patients alike, digital X-rays represent a superior, more efficient, and safer option.

How to Use Digital X-ray Machines?

Using a digital X-ray machine is a straightforward and efficient process. After positioning the patient, the machine settings are adjusted according to the required diagnostic information. Once the X-ray is taken, the image is captured by a flat-panel detector and instantly transferred to a computer. The digital interface allows healthcare professionals to enhance, zoom, and analyze the images directly on the screen, ensuring accurate diagnosis and improved patient care.

How Much Does a Digital X-ray Cost?

The cost of a digital X-ray machine can vary based on factors such as brand, features, and whether the machine is portable or stationary. While the initial investment for a DR system is higher than that for an analog X-ray machine, the long-term savings are significant. Without the recurring expenses of film, chemicals, and storage, clinics can quickly recover their initial investment. Furthermore, the enhanced diagnostic capabilities and increased patient throughput offered by digital X-rays can lead to higher revenue, making them a more economical choice in the long term. 

Where Can We Get the Cost-Efficient Digital X-ray Machines?

If you're looking for cost-effective and reliable digital X-ray machines, China is an excellent source. Chinese manufacturers, known for their innovation and quality, offer some of the most competitively priced and advanced digital X-ray systems available on the market today. Guangzhou Hengya Medical Equipment Co., Ltd., a leading supplier in the industry, provides a range of digital X-ray machines that combine cutting-edge technology with affordability. With Hengya Medical, you can find machines that meet your clinic’s needs without compromising on quality or service. For inquiries and purchases, you can reach out directly to Hengya Medical Equipment to explore your options and secure the best deal for your healthcare facility.

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[industrynewsupdates]

Lab Supplies Procurement Intelligence Competitive Landscape

The global lab supplies category is anticipated to grow at a CAGR of 7.5% from 2023 to 2030. Growth of the category can be attributed to a rise in life science research and clinical laboratory testing, and growth in financial support and investment for biotechnology and pharmaceutical research & development. The category is anticipated to witness steady growth over the forecasted timeframe due to uninterrupted and ongoing supply of laboratory equipments. Over time, laboratories have evolved into multifunctional research spaces where a wide range of testing procedures and comparison studies are conducted. The market need for laboratory supplies has increased as a result of this. In addition, the field of lab supply research has become increasingly dominant over the past ten years. As a result, academic institutions have expanded their labs, which has further fuelled the category's growth.

Technologies that drive the global category include automation, cloud, advanced analytics, smart lab devices, single-use technologies, nanotechnology, and 3D-printing. Workflows in laboratories are being revolutionized by automation, which reduces human error and streamline repetitive operations. Faster and more precise data generation is made possible by robotic devices for high-throughput screening, chemical synthesis, and sample handling. in addition, latest lab equipments are capable in recording data and adding it on cloud. The apparatus can also notify a scientist or lab technician in case of malfunction. Furthermore, Researchers are becoming more knowledgeable about intricate chemical systems because of developments in analytical techniques. Unmatched detail is being provided by methods like electron microscopy, NMR (nuclear magnetic resonance) spectroscopy, and HRMS (high-resolution mass spectrometry), which is propelling advancements in disciplines like drug development, materials research, and metabolomics.

Order your copy of the Lab Supplies Procurement Intelligence Report, 2023 - 2030, published by Grand View Research, to get more details regarding day one, quick wins, portfolio analysis, key negotiation strategies of key suppliers, and low-cost/best-cost sourcing analysis

The category for lab supplies is fragmented, with the presence of regional and global suppliers. Players in the industry are investing heavily in improving existing products and launching new products with cutting-edge features and technologies to streamline sampling operations. For instance, in 2022, Waters Corporation released ‘Extraction+ Connected Device’ which records & automates solid phase extraction technique utilized in sample preparation for research applications in clinical studies, environmental, forensic, food, and biological applications. In addition, the players are indulging in activities such as mergers & acquisitions, partnerships, etc. to increase their market share and stay competitive. Since the category is fragmented, the buyers in this category possess higher negotiation power as they can look for alternative providers who can provide at a lower cost with better quality. However bargaining power of big players is still high owing to their operational and functional capabilities, making it challenging for the buyers to get the price of their choice.

Cost of products (equipments, disposables, reagents), labor cost, transportation cost and insurance cost are the key cost components in this category. In 2022, the cost of raw materials reached all-time highs for plastic converters in North America, Europe, and Asia. Also, the price of consumables getting shipped from North America, Europe, and Asia got affected by the Ukraine-Russia conflict. Goods being transported by rail from China has increased recently, which has decreased the need for shipping containers as well as the costs connected with gasoline for transportation. The prices of centrifuges offered in the category ranges from USD 27 to USD 63,000 depending on type of centrifuge (mini, micro and benchtop), RPM speed and relative centrifugal field (RCF). In addition, the prices of incubators offered in the category ranges from USD 31 to USD 49,900 depending on chamber size, temperature ranges, and features (smartphone notification, alarms, etc.)

North America region dominates the global lab supplies category, holding over 37.6% of global market share. The need for products offered in the category throughout the region is being greatly influenced by rising research & development investments in number of industries, including chemicals and pharmaceuticals in the United States. In addition, favourable government regulations, active engagement of FDA in monitoring clinical test findings and advances, and the growing number of approvals is further supporting the growth of the category in the region. Furthermore, assessing the range of products offered by a supplier, lead time being guaranteed by a supplier, ensuring that the supplier offers technical assistance post sales, comparing the prices offered by different suppliers are some of the best sourcing practices considered in this category.

Browse through Grand View Research’s collection of procurement intelligence studies:

• Drug Testing Procurement Intelligence Report, 2023 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

• Ammonia Procurement Intelligence Report, 2023 - 2030 (Revenue Forecast, Supplier Ranking & Matrix, Emerging Technologies, Pricing Models, Cost Structure, Engagement & Operating Model, Competitive Landscape)

Lab Supplies Procurement Intelligence Report Scope

• Lab Supplies Category Growth Rate: CAGR of 7.5% from 2023 to 2030

• 5% - 10% increase (Annually): Pricing Models

• Cost-plus pricing, Fixed pricing: Supplier Selection Scope: Cost and pricing, Past engagements, Productivity, Geographical presence

• Supplier Selection Criteria: Industries served, years in service, geographic service provision, certifications, types of products, features, technical support, lead time, regulatory compliance, and others

• Report Coverage: Revenue forecast, supplier ranking, supplier matrix, emerging technology, pricing models, cost structure, competitive landscape, growth factors, trends, engagement, and operating model

Key Companies 

• Agilent Technologies, Inc.

• Becton

• Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Danaher Corporation

• Hilton Instruments Ltd.

• Medline Industries, LP

• PerkinElmer Inc.

• Sartorius AG

• Shimadzu Corporation

• Th. Geyer GmbH & Co. KG

• Thermo Fisher Scientific Inc.

• Waters Corporation

Brief about Pipeline by Grand View Research:

A smart and effective supply chain is essential for growth in any organization. Pipeline division at Grand View Research provides detailed insights on every aspect of supply chain, which helps in efficient procurement decisions.

Our services include (not limited to):

• Market Intelligence involving – market size and forecast, growth factors, and driving trends

• Price and Cost Intelligence – pricing models adopted for the category, total cost of ownerships

• Supplier Intelligence – rich insight on supplier landscape, and identifies suppliers who are dominating, emerging, lounging, and specializing

• Sourcing / Procurement Intelligence – best practices followed in the industry, identifying standard KPIs and SLAs, peer analysis, negotiation strategies to be utilized with the suppliers, and best suited countries for sourcing to minimize supply chain disruptions

[futuristicpaintercat]

Protein Chip Market will grow at highest pace owing to rising demand for personalized medicines

Protein chips are microarrays used for protein analysis. Protein chips allow for high-throughput analysis of proteomics and can be used for applications like disease diagnosis, drug discovery, and toxicity testing. Protein chips have advantages like being miniaturized, cost-effective and enabling parallel detection of multiple biomolecular interactions simultaneously. The growing need for early and accurate disease diagnosis, increasing focus on personalized medicine, and rising investments in proteomics research are fueling the demand for protein chips in the healthcare industry. The Global Protein Chip Market is estimated to be valued at US$ 2.23 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031. Key Takeaways Key players operating in the Protein Chip Market Companies are Agilent Technologies, PerkinElmer, Bio-Rad Laboratories, Thermo Fisher Scientific, Illumina, Shimadzu Corporation, Roche Diagnostics, RayBiotech, Danaher, Sengenics, Microarrays Inc, Arrayit Corporation, Affymetrix, Ciphergen, Whatman, Biacore, Zyomyx. Agilent Technologies and Illumina occupy a significant share of the market owing to their expansive product portfolio and global presence.

The demand for protein chips is growing significantly due to increased investments in proteomics research by pharmaceutical and biotechnology companies. Protein chips find wide applications in drug discovery, disease diagnosis, and toxicity analysis. Technological advancements have enhanced the detection capabilities of protein chips. Recent advances like automated protein arrays have improved throughput and reproducibility. Miniaturization of protein chips has enabled analysis of low sample volumes, thereby reducing reagent costs. Market Trends One of the Protein Chip Market Demand is increased integration with microfluidics. Integrating microfluidics allows for automated sample processing and analysis on protein chips. This enhances throughput and minimizes sample and reagent volumes required. Another major trend is the development of multiplexed protein chips that enable high-throughput screening of multiple proteins and protein interactions simultaneously (Nandakumar et al., 2022). This aids in rapid diagnostics and systems biology applications. The Asia Pacific region is projected to be the fastest growing market for protein chips during the forecast period from 2024 to 2031. This is due to increasing government investments and expanding research activities in countries like China, Japan and India. Rising health expenditure, growing biotechnology industry and rise of Asia's big pharma are some important factors supporting the protein chip market growth in the Asia Pacific region.

Get more insights on Protein Chip Market 

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)

[credenceresearchdotblog]

The global demand for Healthcare Analytical Testing was valued at USD 6715.2 Million in 2023 and is expected to reach USD 18031.7 Million in 2032, growing at a CAGR of 11.60% between 2024 and 2032.The healthcare analytical testing market has witnessed significant growth in recent years, driven by advancements in technology, an increasing emphasis on quality and safety in healthcare, and the rising demand for precision medicine. This market encompasses a wide range of services, including bioanalytical testing, environmental monitoring, stability testing, and raw material testing, among others. The convergence of these services is crucial in ensuring the efficacy, safety, and compliance of pharmaceutical and biotechnological products.

Browse the full report at https://www.credenceresearch.com/report/healthcare-analytical-testing-market

Market Overview

The global healthcare analytical testing market is projected to grow at a substantial rate, with estimates suggesting a compound annual growth rate (CAGR) of over 10% during the forecast period. The market's expansion is attributed to several factors, including the increasing R&D investments in the pharmaceutical and biotechnology sectors, stringent regulatory requirements, and the rising prevalence of chronic diseases which necessitates the development of new and effective therapies.

Key Drivers

1. Technological Advancements: Innovations in analytical testing technologies, such as high-throughput screening, next-generation sequencing, and advanced mass spectrometry, have revolutionized the healthcare analytical testing landscape. These technologies offer higher accuracy, efficiency, and speed, enabling the rapid analysis of complex biological samples.

2. Regulatory Compliance: Regulatory bodies such as the FDA (Food and Drug Administration), EMA (European Medicines Agency), and other global regulatory authorities have stringent guidelines for the quality and safety of healthcare products. Compliance with these regulations necessitates comprehensive analytical testing, driving the demand for these services.

3. Growing Biopharmaceutical Sector: The biopharmaceutical industry is booming, with a surge in the development of biologics, biosimilars, and personalized medicine. Analytical testing plays a pivotal role in the biopharmaceutical sector, ensuring the safety, potency, and purity of these complex products.

4. Rising Prevalence of Chronic Diseases: The global burden of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is increasing. This has led to a heightened demand for new therapeutic solutions, subsequently driving the need for rigorous analytical testing to ensure the efficacy and safety of these treatments.

Segmentation

The healthcare analytical testing market can be segmented based on service type, end-user, and region.

1. Service Type: The market offers a variety of services, including bioanalytical testing, physical characterization, method validation, stability testing, and raw material testing. Bioanalytical testing holds a significant share due to its critical role in drug development and clinical trials.

2. End-User: Major end-users of healthcare analytical testing services include pharmaceutical and biopharmaceutical companies, contract research organizations (CROs), and academic and government research institutions. Pharmaceutical and biopharmaceutical companies are the largest consumers, driven by their extensive R&D activities.

3. Region: Geographically, North America dominates the market, followed by Europe. The presence of leading pharmaceutical companies, advanced healthcare infrastructure, and supportive regulatory frameworks contribute to the dominance of these regions. The Asia-Pacific region is expected to witness the highest growth rate, attributed to the increasing R&D activities, growing healthcare expenditure, and the rising number of contract research organizations in countries like China and India.

Challenges

Despite the robust growth, the healthcare analytical testing market faces several challenges. High costs associated with advanced analytical instruments and the need for skilled professionals to operate these sophisticated technologies can be barriers for some organizations. Additionally, stringent regulatory requirements, while driving market demand, also pose compliance challenges that can be resource-intensive.

Future Outlook

The future of the healthcare analytical testing market looks promising, with continued advancements in technology and increasing investments in healthcare R&D. The rise of personalized medicine and the growing focus on preventive healthcare are expected to create new opportunities for analytical testing services. Moreover, the integration of artificial intelligence (AI) and machine learning (ML) in analytical testing processes is anticipated to enhance the accuracy and efficiency of testing, further propelling market growth.

Key Players

PPD, Inc

ICON plc

LabCorp

Charles River Laboratories International, Inc.

Syneos Health

SGS SA

Eurofins Scientific

Pace Analytical Services, LLC

Toxikon, Inc.

Intertek Group

Segmentation

By Type of Testing:

Pharmaceutical Testing

Medical Device Testing

Biotechnology Testing

Clinical Testing

By Service Type:

Bioanalytical Testing

Physical Characterization

Method Development and Validation

Stability Testing

Microbial Testing

Chemical Testing

Raw Material Testing

Batch Release Testing

Others

By End-User:

Pharmaceutical and Biopharmaceutical Companies

Contract Research Organizations (CROs)

Medical Device Companies

Clinical Research Institutes

Hospitals and Clinics

By Testing Equipment:

Chromatography Systems (HPLC, GC)

Mass Spectrometry (MS)

Spectroscopy (UV-Vis, IR, NMR)

Molecular Testing (PCR, DNA Sequencing)

Imaging Systems

Microbiology Testing Equipment

Others

By Technology:

Liquid Chromatography

Gas Chromatography

Atomic Absorption Spectroscopy

Nuclear Magnetic Resonance (NMR)

Polymerase Chain Reaction (PCR)

Enzyme-Linked Immunosorbent Assay (ELISA)

Others

By Sample Type:

Raw Materials

Intermediates

Finished Products

Environmental Samples

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/healthcare-analytical-testing-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[health-views-updates]

Life Science Tools Market Forecast: Emerging Trends and Key Insights

Life Science Tools Market Outlook, Scope & Overview:

Industry reports indicate that the global life science tools market was valued at USD 160.93 billion in 2023 and is projected to reach USD 370.34 billion by 2031, growing at a CAGR of 10.98% over the forecast period 2024-2031.

Technological Advancements to Drive Growth of Global Life Science Tools Market

The adoption of advanced life science tools and technologies will continue to influence global market revenues. Researchers and healthcare providers are increasingly utilizing life science tools to drive innovations in drug discovery, diagnostics, and personalized medicine.

As a product segment, genomic analysis tools currently hold a significant share of the global life science tools market. This segment is anticipated to grow at a year-over-year rate of 10.98% in 2024 over 2023 and reach USD 370.34 billion in revenues by 2031. The increasing demand for genomic research and the rise in applications of genomics in precision medicine are expected to drive market growth.

Get a Free Sample Report: https://www.snsinsider.com/sample-request/3833

Life Science Tools Solutions – Market Dynamics

Drivers:

Life science tools are witnessing significant growth in the global market due to their critical role in accelerating research and development in the pharmaceutical and biotechnology sectors. The advancements in technologies such as next-generation sequencing (NGS), CRISPR gene editing, and high-throughput screening are enhancing the capabilities of life science research, thereby driving the adoption of these tools. Additionally, the increasing focus on personalized medicine and the rising investments in healthcare infrastructure are key factors driving market growth.

Restraints:

Despite the growth potential, challenges such as high costs associated with advanced life science tools, regulatory compliance requirements, and the complexity of integrating these tools into existing laboratory workflows are hindering the widespread adoption of life science tools. Moreover, concerns about data security and privacy, as well as the need for specialized training for researchers, pose additional challenges to market expansion.

Life Science Tools Solutions – Market Outlook

The proven benefits of life science tools in enhancing research capabilities, improving diagnostic accuracy, and accelerating drug development have contributed to the market's growth. Life science tools are expected to witness increased adoption across major research markets, including North America, Europe, and Asia Pacific, driven by technological advancements and the growing focus on precision medicine and personalized healthcare.

Global Life Science Tools Market

The rise in demand for life science tools in developed and emerging markets is expected to drive market growth over the forecast period. North America currently holds a significant market share in the global life science tools market, with the US being a key contributor to market revenues. Europe and Asia Pacific regions are also experiencing rapid adoption of life science tools, supported by favorable regulatory frameworks and increasing investments in research and development.

Key Players in the Life Science Tools Market

Leading companies in the life science tools market include Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, and Illumina, Inc. These companies are at the forefront of developing and commercializing advanced life science tools for various applications, including genomic research, proteomics, and cell biology.

In conclusion, the global life science tools market is poised for substantial growth over the forecast period, driven by technological advancements, increasing research and development activities, and the expanding adoption of precision medicine and personalized healthcare solutions.

Other Trending Reports

Portable Ultrasound Industry Growth

mRNA Therapeutics Industry Growth

Remote Patient Monitoring (RPM) Industry Growth

Dental Imaging Industry Growth

[businessindustry]

Automated Microscopy Market Size, Global Insights and Trends 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Automated Microscopy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Automated Microscopy Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Automated Microscopy Market?

The global automated microscopy market size reached US$ 108 billion in 2023. Looking forward, Reports and Insights expects the market to reach US$ 293.45 billion in 2032, exhibiting a growth rate (CAGR) 9.7% of during 2024-2032.

What are Automated Microscopy?                                                                                                                                                                            

Automated microscopy is an advanced technology that integrates imaging techniques with automated systems to streamline and improve microscopic analysis. It employs robotic components, high-resolution cameras, and sophisticated software to manage tasks like sample positioning, image capture, and data analysis autonomously. This automation enables high-throughput screening, ensures consistent and reproducible results, and facilitates the analysis of large datasets. Widely used in biomedical research, drug discovery, and materials science, automated microscopy reduces human error and labor, expediting research processes and enhancing the reliability of outcomes.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/2313

What are the growth prospects and trends in the Automated Microscopy industry?

The automated microscopy market growth is driven by various factors and trends. The automated microscopy market is experiencing rapid growth, fueled by technological advancements and a growing need for precise and high-throughput imaging solutions in diverse industries. Key drivers of this expansion include the increasing applications in fields like biomedical research, pharmaceuticals, and materials science, where automated microscopy is improving efficiency and accuracy. Innovations such as AI-driven analysis, enhanced imaging techniques, and integration with laboratory information management systems (LIMS) are further driving market growth. Moreover, rising investments in R&D and the demand for consistent and trustworthy results are driving the global adoption of automated microscopy systems. Hence, all these factors contribute to automated microscopy market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

North America

United States

Canada

Europe

Germany

United Kingdom

France

Italy

Spain

Russia

Poland

Benelux

Nordic

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

ASEAN

Australia & New Zealand

Rest of Asia Pacific

Latin America

Brazil

Mexico

Argentina

Middle East & Africa

Saudi Arabia

South Africa

United Arab Emirates

Israel

Rest of MEA

Who are the key players operating in the industry?

The report covers the major market players including:

Agilent Technologies, Inc.

Nikon Corporation

Carl Zeiss AG

Olympus Corporation

Thermo Fisher Scientific Inc.

Leica Microsystems GmbH

Bruker Corporation

Hitachi High-Technologies Corporation

JEOL Ltd.

Keyence Corporation

View Full Report: https://www.reportsandinsights.com/report/Automated Microscopy-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[healthcaremarketanalysis]

Global Cell Analysis Market Size, Share, Trends and Revenue Forecast 2028

The Global Cell Analysis Market in terms of revenue was estimated to be worth $20.2 billion in 2023 and is poised to reach $33.9 billion by 2028, growing at a CAGR of 10.9% from 2023 to 2028.

Attractive Opportunities in the Cell Analysis Market

Download PDF Brochure:

Cell Analysis Industry Dynamics

DRIVER: Growing number of drug discovery activities

Adoption of cell-based screening assays has increased in he drug discovery activities to understand associated complexities. Additionally, advances in cell biology, bioinformatics, molecular biology, genomics, and proteomics have generated large volumes of data, owing to which the use of cell-based assays in the drug development process has gained importance. Similarly, the Human Genome Project has generated a number of targets on which drug screening experiments can be carried out. This rapid expansion in drug targets and drug leads in recent years has accelerated the development of cell-based assays for primary and secondary screening in drug discovery.

RESTRAINT: High cost of instruments and restrictions on reagent use

The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell analysis has increased their reliability. However, these technologies have also resulted in a significant increase in the cost of instruments. Moreover, the time and cost involved in each HTS process are directly proportional to the target molecule’s complexity; consequently, the higher the complexity, the greater the cost. In biopharmaceutical companies, the overall cost of production of biopharmaceuticals has increased considerably due to the use of these expensive systems.

OPPORTUNITY: Application of novel cell-based assays in cancer research

In the last few decades, the incidence and prevalence of cancer have increased significantly across the globe, and this trend is expected to continue in the coming years. In an effort to reduce cancer incidence and mortality, the demand for novel approaches that offer effective cancer diagnosis and treatment has increased in recent years. In this regard, some recent studies have been published that highlight the importance of cell-based assays in cancer research.

The software segment of the cell analysis industry is expected to grow at the highest rate during the forecast period

Based on product & service, the global cell analysis market is segmented into reagents & consumables, instruments, accessories, software, and services. The reagents & consumables segment accounted for the largest share of the market in 2022. Prominent companies are providing flow cytometry reagents as directly conjugated products. Companies are introducing high-quality reagents with an enhanced geographic reach contributing to the largest share of the reagents & consumables market. Innovative offerings addressing complex datasets with multiple analytical modalities for effective interpretation is the key contributing factor to the segment’s fastest growth.

Request 10% Customization:

The flow cytometry technique dominated the cell analysis industry

Based on technique, the global cell analysis market is segmented into flow cytometry, PCR, cell microarrays, microscopy, spectrophotometry, high-content screening, and other techniques. The flow cytometry segment accounted for the largest market share in 2022. Increase in demand for flow cytometry in single-cell analysis studies to analyze multiple characteristics of the sample at single-cell level is the key driving factor of this segment. Additionally, high-content screening segment has registerd highest growth ratefrom 2023-2028, with high demand for HCS products in cell behavior studies.

The single-cell analysis segment of the cell analysis industry is expected to register the highest CAGR during the forecast period

Based on process, the global cell analysis market is segmented into cell identification, cell viability, cell signaling pathway/signal transduction, cell proliferation, cell counting & quality control, cell interaction, cell structure study, target identification & validation, and single-cell analysis. Cell identification accounted for the largest market share of in 2022. High adoption of cell identification products across industrial applications, including food and healthcare is a key contributing factor to the segment growth. Cell identification is crucial to drug discovery and high adoption of these products have propelled companies to introduce innovative products. On the other hand, single-cell analysis segment is expected to grow at the fastest pace during the forecast period. Single-cell analysis has gained significant traction over the years for assessment of individual cells at multi-parametric level, contributing to the segment growth.

The pharmaceutical & biotechnology companies accounted for the largest share in the cell analysis industry

Based on end user, the cell analysis market is segmented into pharmaceutical & biotechnology companies, hospitals & clinical testing laboratories, academic & research institutes, and other end users. The other end users are inclusive of forensic laboratories, blood banks, CROs, food & beverage manufacturers, and environmental monitoring organizations. The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2022. Frequent adoption of consumables and instruments across different steps in drug discovery & development has led to the dominance of pharmaceutical & biotechnology end users. Additionally, hospitals and clinical testing laboratories segment is anticipated to grow at the fastest pace throughout the forecast period. Adoption of highly complex and specialized assays across this end user segment is expected to support its rapid growth.

North America was the largest regional market for cell analysis industry in 2022.

Geographically, the cell analysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region is expected to dominate the market through 2021-2028, followed by Europe. The US pharmaceutical industry has witnessed tremendous growth due to the increasing approval of first-in-class drugs by the Food and Drugs Administration (FDA), rising R&D expenditure by pharmaceutical companies, and the establishment of startups focusing on developing promising drugs for rare diseases and neurological conditions. This has propelled cell-based research activities, offering lucrative opportunities for the growth of the market in the US. Asia Pacific market is expected to grow at the fastest pace through 2023 to 2028.

Prominent Players:

Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).

Recent Developments of Cell Analysis Industry

In 2023, Becton, Dickinson and Company (US) launched a Spectral Cell Sorter that is coupled with high-speed cell imaging. this product combines real-time imaging technology with spectral flow cytometry.

In 2020, Miltenyi Biotec (Germany) launched MACS GMP Tyto Cartridge, a GMP-compliant cell sorter..

In 2020, Bio-Rad Laboratories, Inc. (US) acquired Celsee, Inc., a provider of instruments and consumables for the isolation, detection, and analysis of single cells. This acquisition expanded the company’s product offerings in the flow cytometry market.

Cell Analysis Industry Advantages:

Comprehensive Understanding: Cell analysis techniques enable researchers to gain a comprehensive understanding of cellular behavior and function. By analyzing various cellular parameters, such as morphology, gene expression, protein levels, and metabolic activity, researchers can unravel complex biological processes and uncover underlying mechanisms of diseases.

Personalized Medicine: Cell analysis plays a crucial role in advancing personalized medicine. By studying individual cells, researchers can identify biomarkers that are specific to certain diseases or patient populations. This information enables the development of targeted therapies and personalized treatment strategies, optimizing patient outcomes.

Drug Discovery and Development: The cell analysis market contributes significantly to drug discovery and development. By using high-throughput screening and cell-based assays, researchers can evaluate the efficacy and toxicity of potential drug candidates. This helps in identifying promising drug candidates early in the development process, reducing costs and improving success rates.

Advancements in Technology: The cell analysis industry benefits from continuous advancements in technology. Innovations such as automated imaging systems, flow cytometry, single-cell sequencing, and high-resolution microscopy have enhanced the accuracy, efficiency, and throughput of cell analysis techniques. These technological advancements enable researchers to generate large-scale data sets and obtain more precise insights into cellular behavior.

Translational Research: Cell analysis facilitates translational research by bridging the gap between basic research and clinical applications. The findings from cellular studies can be translated into clinical diagnostics, prognostics, and therapeutics. This integration helps in improving patient care, developing novel treatment approaches, and accelerating the adoption of scientific discoveries into clinical practice.

Quality Control and Safety Testing: Cell analysis techniques play a vital role in quality control and safety testing in industries such as pharmaceuticals, biotechnology, and food and beverages. These methods ensure that products meet regulatory standards, evaluate potential toxicity, and verify the absence of contaminants, ensuring consumer safety.

Academic and Industrial Collaboration: The cell analysis market encourages collaboration between academic institutions, research organizations, and industries. This collaboration fosters knowledge exchange, accelerates innovation, and promotes interdisciplinary research, leading to advancements in both scientific understanding and practical applications

[healthcarehubhh]

The Gas Chromatography Market to grow at highest pace owing to widespread applications in drug discovery and development processes

The gas chromatography market involves the use of gas chromatographs for separation and analysis of mixtures. Gas chromatography is commonly used in analytical chemistry for separating and analyzing compounds that can be vaporized without decomposition. It works on the principle that different compounds move through a column at different rates depending on their molecular characteristics and affinity with the column’s stationary phase. Some key applications of gas chromatography include drug discovery and development, analysis of environmental pollutants, quality assurance in food and beverage industry. It offers several advantages over other analytical techniques like high reproducibility and accuracy, enhanced precision and resolution. The global demand for gas chromatography is rising significantly owing to increasing focus on advanced analytical methods in industries like pharmaceuticals and biotechnology. The Global Gas Chromatography Market is estimated to be valued at US$ $9.64 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030. Key Takeaways Key players operating in the Gas Chromatography are Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Danaher Corporation, Merck KgaA, PerkinElmer, Inc. Agilent Technologies, Inc. dominates the gas chromatography market with over 25% market share owing to its wide product portfolio. Growing demand from drug development and clinical research is a major factor boosting the gas chromatography industry. Pharmaceutical and biotech companies are increasingly adopting GC techniques to accelerate drug discovery processes. Stringent safety and quality regulations across industries are also propelling the demand.

Technological advancements like improved columns, detectors and software are enhancing efficiency and enabling high throughput screening. Miniaturization of gas chromatography systems has augmented their usage in point-of-care testing and on-field applications. Market Trends - Increasing popularity of hyphenated techniques: Combining gas chromatography with mass spectrometry is gaining significance as it provides confirmatory data and enhances sensitivity. - Upsurge in crude and shale oil production: Gas chromatography finds increasing usage in analyzing complex hydrocarbon mixtures obtained from crude oil refining and shale oil extraction. This is expected to drive the demand from oil and gas industry. Market Opportunities - Focus on food safety and authentication: Rising global food trade and recent adulteration incidents have heightened the need for reliable analytical methods for ensuring food safety. This presents opportunities for GC deployment in food testing labs. - Pharmaceutical applications: Growing drug pipelines, complex molecules and stringent regulations make gas chromatography an indispensable analytical technique. Increase in outsourcing of clinical trials and quality control to Asia and Latin America opens new expansion avenues. Impact of COVID-19 on the Gas Chromatography Market The COVID-19 pandemic has significantly impacted the growth of the gas chromatography market. During the initial outbreak, countries went under complete lockdown which disrupted the supply chain and halted production activities. This led to a significant decline in sales of gas chromatography instruments and consumables in 2020. Research and development activities were also put on hold as most laboratories were shut down during the peak of the pandemic.